Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Purple Innovation, Inc. stock logo
PRPL
Purple Innovation
$1.60
+6.7%
$1.67
$0.55
$3.78
$171.54M1.98846,901 shs389,961 shs
ThredUp Inc. stock logo
TDUP
ThredUp
$1.56
$1.88
$1.52
$4.39
$169.23M0.64533,884 shs281,659 shs
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$2.53
+2.8%
$2.60
$0.50
$3.89
$473.16M0.292.63 million shs1.46 million shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Purple Innovation, Inc. stock logo
PRPL
Purple Innovation
+6.67%+2.24%+5.26%+55.34%-41.82%
ThredUp Inc. stock logo
TDUP
ThredUp
+0.32%+0.32%-19.01%-31.80%-44.17%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
+2.85%-1.75%-22.15%+72.11%+279.99%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Purple Innovation, Inc. stock logo
PRPL
Purple Innovation
2.4777 of 5 stars
3.33.00.00.00.05.00.6
ThredUp Inc. stock logo
TDUP
ThredUp
2.2449 of 5 stars
3.31.00.00.02.24.20.6
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
2.0849 of 5 stars
4.51.00.00.01.91.70.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Purple Innovation, Inc. stock logo
PRPL
Purple Innovation
2.67
Moderate Buy$3.95146.88% Upside
ThredUp Inc. stock logo
TDUP
ThredUp
2.60
Moderate Buy$3.67135.80% Upside
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
3.00
Buy$6.88171.74% Upside

Current Analyst Ratings

Latest TSHA, TDUP, and PRPL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/18/2024
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$7.00
4/11/2024
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00
4/9/2024
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$9.00
3/21/2024
Purple Innovation, Inc. stock logo
PRPL
Purple Innovation
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$2.50
3/21/2024
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00
3/21/2024
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$5.00 ➝ $7.00
3/20/2024
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$5.00
3/20/2024
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$7.00
3/20/2024
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$5.00 ➝ $7.00
3/13/2024
Purple Innovation, Inc. stock logo
PRPL
Purple Innovation
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$1.25 ➝ $2.25
3/13/2024
Purple Innovation, Inc. stock logo
PRPL
Purple Innovation
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$1.00 ➝ $2.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Purple Innovation, Inc. stock logo
PRPL
Purple Innovation
$510.54M0.34N/AN/A$1.09 per share1.47
ThredUp Inc. stock logo
TDUP
ThredUp
$322.02M0.53N/AN/A$0.96 per share1.62
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$15.45M30.63N/AN/A$0.40 per share6.33

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Purple Innovation, Inc. stock logo
PRPL
Purple Innovation
-$120.76M-$1.11N/AN/AN/A-22.31%-42.60%-16.77%5/8/2024 (Estimated)
ThredUp Inc. stock logo
TDUP
ThredUp
-$71.25M-$0.68N/AN/AN/A-22.12%-61.27%-26.23%5/6/2024 (Confirmed)
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-$111.57M-$0.67N/AN/AN/A-722.06%N/A-55.72%5/9/2024 (Estimated)

Latest TSHA, TDUP, and PRPL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2024N/A
ThredUp Inc. stock logo
TDUP
ThredUp
-$0.14N/A+$0.14N/AN/AN/A  
3/19/2024Q4 2023
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
N/A$0.35+$0.35-$0.22$4.75 million$3.60 million
3/12/2024Q4 2023
Purple Innovation, Inc. stock logo
PRPL
Purple Innovation
-$0.19-$0.15+$0.04-$0.13$145.43 million$145.94 million
3/4/202412/31/2023
ThredUp Inc. stock logo
TDUP
ThredUp
-$0.13-$0.14-$0.01-$0.14$80.30 million$81.39 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Purple Innovation, Inc. stock logo
PRPL
Purple Innovation
N/AN/AN/AN/AN/A
ThredUp Inc. stock logo
TDUP
ThredUp
N/AN/AN/AN/AN/A
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Purple Innovation, Inc. stock logo
PRPL
Purple Innovation
0.23
1.28
0.68
ThredUp Inc. stock logo
TDUP
ThredUp
0.21
1.22
1.02
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
0.54
4.08
4.08

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Purple Innovation, Inc. stock logo
PRPL
Purple Innovation
88.41%
ThredUp Inc. stock logo
TDUP
ThredUp
89.08%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
77.70%

Insider Ownership

CompanyInsider Ownership
Purple Innovation, Inc. stock logo
PRPL
Purple Innovation
48.30%
ThredUp Inc. stock logo
TDUP
ThredUp
34.42%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
2.25%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Purple Innovation, Inc. stock logo
PRPL
Purple Innovation
1,700107.21 million55.43 millionOptionable
ThredUp Inc. stock logo
TDUP
ThredUp
2,377108.83 million71.37 millionOptionable
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
52187.02 million182.81 millionOptionable

TSHA, TDUP, and PRPL Headlines

SourceHeadline
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from AnalystsTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from Analysts
americanbankingnews.com - April 20 at 5:06 AM
Cantor Fitzgerald Reiterates "Overweight" Rating for Taysha Gene Therapies (NASDAQ:TSHA)Cantor Fitzgerald Reiterates "Overweight" Rating for Taysha Gene Therapies (NASDAQ:TSHA)
americanbankingnews.com - April 20 at 4:32 AM
Taysha Gene Therapies (NASDAQ:TSHA) Stock Rating Reaffirmed by Cantor FitzgeraldTaysha Gene Therapies (NASDAQ:TSHA) Stock Rating Reaffirmed by Cantor Fitzgerald
marketbeat.com - April 18 at 10:28 AM
Certain Biotech Investors Get an Early Look at Results. Is That Fair?Certain Biotech Investors Get an Early Look at Results. Is That Fair?
finance.yahoo.com - April 15 at 8:46 AM
Vanguard Group Inc. Has $16.84 Million Stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Vanguard Group Inc. Has $16.84 Million Stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)
marketbeat.com - April 15 at 4:15 AM
Taysha Gene Therapies (NASDAQ:TSHA)  Shares Down 7.5% Taysha Gene Therapies (NASDAQ:TSHA) Shares Down 7.5%
americanbankingnews.com - April 14 at 6:08 AM
Impact and Outlook: Taysha Gene Therapies Stock AnalysisImpact and Outlook: Taysha Gene Therapies Stock Analysis
markets.businessinsider.com - April 11 at 1:56 PM
Taysha Gene Therapies (NASDAQ:TSHA) Given "Buy" Rating at Needham & Company LLCTaysha Gene Therapies (NASDAQ:TSHA) Given "Buy" Rating at Needham & Company LLC
marketbeat.com - April 11 at 8:32 AM
Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 3%Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 3%
marketbeat.com - April 10 at 12:36 PM
Taysha draws bullish view at Piper Sandler on lead assetTaysha draws bullish view at Piper Sandler on lead asset
msn.com - April 9 at 7:15 PM
Buy Rating on Taysha Gene Therapies with TSHA-102 Poised to Transform Rett Syndrome Treatment and Drive Revenue GrowthBuy Rating on Taysha Gene Therapies with TSHA-102 Poised to Transform Rett Syndrome Treatment and Drive Revenue Growth
markets.businessinsider.com - April 9 at 9:14 AM
Evaluating Taysha Gene Therapies: Insights From 7 Financial AnalystsEvaluating Taysha Gene Therapies: Insights From 7 Financial Analysts
markets.businessinsider.com - April 9 at 9:14 AM
Piper Sandler Begins Coverage on Taysha Gene Therapies (NASDAQ:TSHA)Piper Sandler Begins Coverage on Taysha Gene Therapies (NASDAQ:TSHA)
marketbeat.com - April 9 at 8:30 AM
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - April 5 at 8:00 AM
Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 5.1%Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 5.1%
marketbeat.com - April 4 at 2:24 PM
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down to $2.71Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down to $2.71
marketbeat.com - April 3 at 1:36 PM
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 2.6%Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 2.6%
marketbeat.com - March 26 at 12:59 PM
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by AnalystsTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by Analysts
marketbeat.com - March 26 at 5:01 AM
Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call TranscriptTaysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 21 at 6:44 PM
Buy Rating on Taysha Gene Therapies Anchored by Promising TSHA-102 Clinical Data and Upcoming Pediatric Study CatalystsBuy Rating on Taysha Gene Therapies Anchored by Promising TSHA-102 Clinical Data and Upcoming Pediatric Study Catalysts
markets.businessinsider.com - March 21 at 8:29 AM
Taysha Gene Therapies Full Year 2023 Earnings: Beats ExpectationsTaysha Gene Therapies Full Year 2023 Earnings: Beats Expectations
finance.yahoo.com - March 21 at 8:29 AM
Buy Rating Affirmed for Taysha Gene Therapies Amid Positive Clinical Progress and Robust Financial HealthBuy Rating Affirmed for Taysha Gene Therapies Amid Positive Clinical Progress and Robust Financial Health
markets.businessinsider.com - March 21 at 3:28 AM
Taysha Gene Therapies Shares Jump On Initial Data From First Pediatric Patient With Rare Neurodevelopmental DisorderTaysha Gene Therapies Shares Jump On Initial Data From First Pediatric Patient With Rare Neurodevelopmental Disorder
msn.com - March 20 at 5:21 PM
Buy Rating Reaffirmed for Taysha Gene Therapies Amid Clinical Progress and Financial StabilityBuy Rating Reaffirmed for Taysha Gene Therapies Amid Clinical Progress and Financial Stability
markets.businessinsider.com - March 20 at 5:21 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Purple Innovation logo

Purple Innovation

NASDAQ:PRPL
Purple Innovation, Inc. designs and manufactures sleep and other products in the United States and internationally. The company offers mattresses, pillows, cushions, bases, sheets, platforms, adjustable bases, mattress protectors, foundations, blankets, duvets, duvet covers, seat cushions, and pet beds under the Purple brand. It markets and sells its products through its e-commerce online channels, retail brick-and-mortar wholesale partners, third-party online retailers, and Purple showrooms, as well as through its website, Purple.com. The company was founded in 2010 and is headquartered in Lehi, Utah.
ThredUp logo

ThredUp

NASDAQ:TDUP
ThredUp Inc., together with its subsidiaries, operates an online resale platform in the United States and internationally. Its platform enables consumers to buy and sell primarily secondhand apparel, shoes, and accessories. ThredUp Inc. was incorporated in 2009 and is headquartered in Oakland, California.
Taysha Gene Therapies logo

Taysha Gene Therapies

NASDAQ:TSHA
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.